TY - JOUR
T1 - Human milk oligosaccharide profiles and child atopic dermatitis up to 2 years of age
T2 - The Ulm SPATZ Health Study
AU - Siziba, Linda P.
AU - Mank, Marko
AU - Stahl, Bernd
AU - Kurz, Deborah
AU - Gonsalves, John
AU - Blijenberg, Bernadet
AU - Rothenbacher, Dietrich
AU - Genuneit, Jon
N1 - Funding Information:
The Ulm SPATZ Health Study was funded through an unrestricted grant by the Medical Faculty of Ulm University. The current research topic was co-funded through a research grant from Danone Nutricia Research, Utrecht, The Netherlands. Nutricia produces and markets infant formula milk containing selected human identical HMOs, amongst other bioactive nutritional components based on scientific evidence. The funders (authors from Danone Nutricia Research) had no role in the design, analysis, or writing of this article. We thank the midwives, nurses, and obstetricians of the Department of Gynaecology and Obstetrics, University Medical Centre Ulm and the caring pediatricians and mothers and their families for their study support and participation. The authors would also like to thank Mrs. Gerlinde Trischler for providing excellent technical assistance. Open access funding enabled and organized by ProjektDEAL.
Funding Information:
The Ulm SPATZ Health Study was funded through an unrestricted grant by the Medical Faculty of Ulm University. The current research topic was co‐funded through a research grant from Danone Nutricia Research, Utrecht, The Netherlands. Nutricia produces and markets infant formula milk containing selected human identical HMOs, amongst other bioactive nutritional components based on scientific evidence. The funders (authors from Danone Nutricia Research) had no role in the design, analysis, or writing of this article.
Publisher Copyright:
© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2022/2
Y1 - 2022/2
N2 - Background: Human milk oligosaccharides (HMOs) have several biological functions. Yet, very few studies have investigated the effect of HMOs on the development of allergies and even fewer on their specific associations with atopic dermatitis (AD) during early childhood. Objective: This study investigated whether individual HMO concentrations, measured at two time points of lactation, were associated with reported diagnosis of AD in children up to two years of age. Method: Outcome data were available for HMOs measured in human milk samples collected at 6 weeks (n = 534) and 6 months (n = 356) of lactation. Associations of HMOs with AD, ascertained from parents and pediatricians at ages one and two years, were assessed in crude and adjusted logistic regression models. Results: Few associations were statistically significant at the conventional level (p <.05), for example, 6-week Lacto-N-neotetraose with 2-year AD [OR 95%CI: 0.82 (0.66, 1.00)] and 6-month 3'-sialyllactose among non-secretor mothers with 1-year AD [2.59 (1.53, 6.81)]. Importantly, accounting for multiple testing, these and all further associations were not statistically significant (all p >.0031, which is the threshold for statistical significance after correction for multiple testing). Conclusion: Our findings suggest that the intake of different levels (or even absence) of the individual HMOs measured at 6 weeks and 6 months of lactation, in the current study, is not significantly associated with the development of AD in early childhood. Given the exploratory nature of our study and the limited sample size, these results should be interpreted with caution. The specific HMOs for which we show plausible associations at conventional level may warrant further research and investigation.
AB - Background: Human milk oligosaccharides (HMOs) have several biological functions. Yet, very few studies have investigated the effect of HMOs on the development of allergies and even fewer on their specific associations with atopic dermatitis (AD) during early childhood. Objective: This study investigated whether individual HMO concentrations, measured at two time points of lactation, were associated with reported diagnosis of AD in children up to two years of age. Method: Outcome data were available for HMOs measured in human milk samples collected at 6 weeks (n = 534) and 6 months (n = 356) of lactation. Associations of HMOs with AD, ascertained from parents and pediatricians at ages one and two years, were assessed in crude and adjusted logistic regression models. Results: Few associations were statistically significant at the conventional level (p <.05), for example, 6-week Lacto-N-neotetraose with 2-year AD [OR 95%CI: 0.82 (0.66, 1.00)] and 6-month 3'-sialyllactose among non-secretor mothers with 1-year AD [2.59 (1.53, 6.81)]. Importantly, accounting for multiple testing, these and all further associations were not statistically significant (all p >.0031, which is the threshold for statistical significance after correction for multiple testing). Conclusion: Our findings suggest that the intake of different levels (or even absence) of the individual HMOs measured at 6 weeks and 6 months of lactation, in the current study, is not significantly associated with the development of AD in early childhood. Given the exploratory nature of our study and the limited sample size, these results should be interpreted with caution. The specific HMOs for which we show plausible associations at conventional level may warrant further research and investigation.
KW - atopic dermatitis (AD)
KW - human milk groups
KW - human milk oligosaccharides (HMOs)
KW - targeted LC-MS/MS
UR - http://www.scopus.com/inward/record.url?scp=85125131916&partnerID=8YFLogxK
U2 - 10.1111/pai.13740
DO - 10.1111/pai.13740
M3 - Article
AN - SCOPUS:85125131916
SN - 0905-6157
VL - 33
SP - 1
EP - 12
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 2
M1 - e13740
ER -